CN112826080A - Culture medium, fermentation culture method thereof and fermentation product capable of improving immunity - Google Patents
Culture medium, fermentation culture method thereof and fermentation product capable of improving immunity Download PDFInfo
- Publication number
- CN112826080A CN112826080A CN202110046373.2A CN202110046373A CN112826080A CN 112826080 A CN112826080 A CN 112826080A CN 202110046373 A CN202110046373 A CN 202110046373A CN 112826080 A CN112826080 A CN 112826080A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- fermentation
- culture medium
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 67
- 230000004151 fermentation Effects 0.000 title claims abstract description 67
- 239000001963 growth medium Substances 0.000 title claims abstract description 38
- 230000036039 immunity Effects 0.000 title claims abstract description 30
- 238000012136 culture method Methods 0.000 title claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 66
- 239000000843 powder Substances 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 10
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 10
- 241001327634 Agaricus blazei Species 0.000 claims abstract description 9
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 9
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 9
- 241000096284 Gynochthodes officinalis Species 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims abstract description 9
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 9
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 8
- 241001556152 Porodaedalea pini Species 0.000 claims abstract description 8
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 7
- 241000272503 Sparassis radicata Species 0.000 claims abstract description 7
- 240000005995 Laetiporus sulphureus Species 0.000 claims abstract description 6
- 235000007714 Laetiporus sulphureus Nutrition 0.000 claims abstract description 6
- 241000190633 Cordyceps Species 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 23
- 241001264174 Cordyceps militaris Species 0.000 claims description 16
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 9
- 241000233866 Fungi Species 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 238000009630 liquid culture Methods 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- 244000061456 Solanum tuberosum Species 0.000 claims description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 241000123150 Fomitopsis pinicola Species 0.000 claims 1
- 244000131360 Morinda citrifolia Species 0.000 claims 1
- 235000008898 Morinda citrifolia Nutrition 0.000 claims 1
- 235000017524 noni Nutrition 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 240000000588 Hericium erinaceus Species 0.000 description 7
- 235000007328 Hericium erinaceus Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 235000001188 Peltandra virginica Nutrition 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 240000008397 Ganoderma lucidum Species 0.000 description 5
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000036983 biotransformation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 241000315067 Hymenopellis radicata Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- NEZONWMXZKDMKF-UHFFFAOYSA-N C.I. Natural Red 20 Chemical compound C1=CC(O)=C2C(=O)C(C(O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 240000004035 Lithospermum officinale Species 0.000 description 1
- 235000011030 Lithospermum officinale Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a culture medium, a fermentation culture method thereof and a fermentation product capable of improving immunity, wherein the culture medium comprises the following components in parts by weight: 3-5 parts of fine powder of long-rooted mushroom, 3-5 parts of fine powder of sparassis crispa, 4-6 parts of fine powder of dendrobium officinale, 2-4 parts of grifola frondosa extract, 3-5 parts of agaricus blazei murill extract, 4-6 parts of morinda officinalis and rhodiola rosea extract, 4-6 parts of poria cocos extract, 1-3 parts of laetiporus sulphureus extract, 3-5 parts of phellinus pini extract, 3-5 parts of galacto-oligosaccharide and 80-100 parts of water. The culture medium is prepared, sterilized, inoculated with Cordyceps and fermented for 7 days. The fermentation product can well improve the immunity activity.
Description
Technical Field
The invention relates to the technical field of biological products, in particular to a culture medium, a fermentation culture method thereof and a fermentation product capable of improving immunity.
Background
The biological product prepared by the biological fermentation technology is the basis for overcoming the best way of utilizing wild resources with limited biomass and realizing the development and utilization of useful metabolites. Compared with the traditional sporocarp cultivation, the production period of the secondary metabolite prepared by liquid fermentation is short, the metabolite is easy to control, and the large-scale production can be realized.
Chinese patent document CN108034590A discloses a culture medium of hericium erinaceus, a biotransformed mycelium, an extract of the biotransformed mycelium, and uses thereof. The culture medium of the hericium erinaceus comprises the following components in parts by weight: 490-350 parts of mung bean, 140-100 parts of wheat bran, 70-50 parts of bran coat and 400-600 parts of water. The biotransformation mycelium is obtained by inoculating Hericium erinaceus into the culture medium and performing mycelium transformation culture. The extract of the biotransformation mycelium is prepared by extracting the mycelium of the hericium erinaceus with water, then concentrating under reduced pressure, and finally freeze-drying in vacuum. The extract of the biotransformation mycelium has immunity enhancing and anti-tumor effects, and can be used for preparing health product or anti-tumor medicine for enhancing immunity. The invention is developed aiming at hericium erinaceus.
Chinese patent document CN108815206A discloses a ganoderma lucidum extract for enhancing immunity and application thereof in preparing food and medicines. The ganoderma lucidum sporocarp involved in the method is obtained by the following steps: inoculating the ganoderma lucidum into a PDA solid culture medium in an inoculation amount of 2-4% (volume/volume), and culturing at 22-28 ℃ in a dark room for 5-7 days to obtain a PDA strain; inoculating the PDA strain into a liquid fermentation culture medium in an inoculation amount of 2-4% (volume/volume), and performing shaking culture at 22-28 ℃ and 170-220 r/min for 5-7 days to obtain a liquid fermentation liquid; adding liquid fermentation liquor into cultivation bags filled with solid fermentation culture medium, wherein 100-400 mL of solid fermentation culture medium and 10-20 mL of liquid fermentation liquor are added into each cultivation bag, and culturing for 5-7 days in a dark room at 22-28 ℃; and opening a side of the cultivation bag, continuously culturing for 40-60 days at the temperature of 22-28 ℃ and the humidity of 85-90%, and harvesting lucid ganoderma sporophores. The liquid fermentation medium comprises the following components: 2-3 g/L of corn flour, 1-2 g/L of bean cake powder, 0.5-3 g/L of bran, 2-4 g/L of glucose, 0.02-0.1 g/L of magnesium sulfate heptahydrate, 0.1-0.2 g/L of monopotassium phosphate, 0.5-3 g/L of yeast powder and the balance of water. The invention is developed aiming at lucid ganoderma.
Although there are various substances for enhancing immunity, the present invention is not developed for hericium erinaceus and ganoderma lucidum, unlike the prior art. The inventor finds that active substances in different substances are organically combined by utilizing a fermentation technology, and a fermentation product can have good immunity-improving activity.
Disclosure of Invention
In view of the above, the present invention is directed to a culture medium, a fermentation culture method thereof, and a fermentation product capable of enhancing immunity, wherein the prepared fermentation product can significantly enhance the immune activity by fermentation culture using the culture medium.
The adopted technical scheme is as follows:
the culture medium for preparing the fermentation product for improving the immunity comprises the following components in parts by weight: 3-5 parts of fine powder of long-rooted mushroom, 3-5 parts of fine powder of sparassis crispa, 4-6 parts of fine powder of dendrobium officinale, 2-4 parts of grifola frondosa extract, 3-5 parts of agaricus blazei murill extract, 4-6 parts of morinda officinalis and rhodiola rosea extract, 4-6 parts of poria cocos extract, 1-3 parts of laetiporus sulphureus extract, 3-5 parts of phellinus pini extract, 3-5 parts of galacto-oligosaccharide and 80-100 parts of water.
Further, the grifola frondosa extract, the agaricus blazei murill extract, the laetiporus sulphureus extract and the phellinus pini gromwell extract are all edible fungus extracts; the edible fungus extracts are prepared by the following method: pulverizing corresponding edible and medicinal fungi, adding 20-30 times of water, extracting in shaking table at 40-50 deg.C for 12 hr, centrifuging to obtain supernatant, concentrating the supernatant under reduced pressure, and vacuum freeze drying to obtain corresponding edible and medicinal fungi extract.
Further, the morinda officinalis extract and the rhodiola rosea extract are prepared by the following method: respectively crushing morinda officinalis and rhodiola rosea, and mixing the raw materials in a weight ratio of 1: mixing at a ratio of 1, adding 20-30 times of 50% vol% ethanol solution, extracting in shaking table at 40 deg.C for 12 hr, filtering to obtain supernatant, concentrating the supernatant under reduced pressure, and vacuum freeze drying to obtain radix Morindae officinalis extract and radix Rhodiolae extract.
In the technical scheme, the content of sulfur-containing amino acid in the oudemansiella radicata is high. The sulfur-containing amino acid can be used for combining choline and creatine in human metabolism, and the creatine is a naturally formed amino acid in organisms, and the amino acid can quickly recover the fatigue of the organisms and can also increase the immunity and explosive force of the organisms. In addition, the oudemansiella radicata polysaccharide has good function of improving immunity.
In addition to enhancing immunity due to increased hematopoietic function, Sparassis crispa has effects in activating TH1 cell and inhibiting TH2 activity, thereby promoting the shift of TH1/TH2 balance towards THI-dominated immunomodulation.
The clinical experimental research of the Grifola frondosa in the United states and Japan shows that the extract can effectively activate human immune cells, such as NK cells, antitoxic T cells, phagocytes and the like, thereby achieving the effects of inhibiting the growth of tumor cells and inducing the apoptosis of cancer cells. Is an excellent immunomodulator.
The polysaccharide content of the agaricus blazei murill is as high as 6.55g/100g, which is 5 times of that of the ganoderma lucidum. The unique beta- (1-6) -D-glucose structure directly acts on immunity, can quickly improve the growth activity of natural immune cells and assists in improving the treatment effect. By enhancing the function of the mononuclear macrophage system, the human body autoimmune function is enhanced, and the effects of inhibiting cell division and regulating immune system reaction are achieved, so that the growth of interfering virus is hindered.
The dendrobium officinale contains rich polysaccharide substances and has the function of enhancing the immunologic function, and the modern pharmacological research shows that the dendrobium officinale can improve the stress capability of a human body and has good functions of resisting fatigue and resisting anoxia;
the Laetiporus sulphureus is warm in nature and sweet in taste, can regulate organism, promote health, resist diseases, and play an important regulating role in human body. The main component of Poria is pachyman with high content. Has inhibitory effect on various bacteria; can reduce gastric acid, and has prophylactic effect on digestive tract ulcer; has obvious protective effect on liver injury; has anti-tumor effect; the immune function can be adjusted in multiple ways; can accelerate the return of leucopenia caused by chemotherapy; and has tranquilizing effect.
Pachymic acid contained in Poria has effects of enhancing immunity, resisting tumor, tranquilizing mind, and lowering blood sugar. Pachyman (pachyman) with a content of up to 75% is a beta (1 → 3) glucopyranose having beta (1 → 6) glucopyranose branched chains, which is cut into beta (1 → 3) glucopyranose having anti-tumor activity.
The Phellinus pini polysaccharide can improve phagocytic ability of macrophage of normal and immunocompromised mice. In addition, the compound can obviously promote the in vitro proliferation capacity of splenocytes, can obviously improve the immunity of organisms, and can be used as a biological effect regulator to be applied to the field of medicines or health-care foods.
Galactooligosaccharides (GOS) are functional oligosaccharides having natural properties, and are excellent nutritional sources and effective proliferation factors for beneficial bacteria such as bifidobacterium, lactobacillus acidophilus and the like in human intestinal tracts, and can improve the digestion and absorption functions of the human intestinal tracts.
The fermentation culture method of the culture medium comprises the following steps:
(1) inoculating the activated Cordyceps militaris strain into a seed liquid culture medium, and performing fermentation culture for 3-7 days to obtain Cordyceps militaris liquid seed liquid;
(2) the cordyceps militaris liquid seed liquid accounting for 2-5% of the volume of the culture medium is inoculated into the culture medium, the cordyceps militaris liquid seed liquid is cultured for 5-8 days at the temperature of 24-27 ℃, the fermentation is finished, and the fermentation liquid is subjected to vacuum freeze drying to obtain a fermentation product with the immunity improving activity.
Further, in the step (1), the seed liquid culture medium comprises the following components in parts by weight: 20 parts of potato, 2 parts of glucose, 0.05 part of magnesium sulfate and 0.02 part of monopotassium phosphate.
Further, the cordyceps militaris strain in the step (1) is selected from cordyceps militaris No. 1.
In the technical scheme, active substances are organically combined or recombined by fermenting cordyceps militaris liquid, and the cordyceps militaris has the function of improving immunity and resisting fatigue.
The fermentation product capable of improving immunity comprises the fermentation product with the immunity improving activity obtained by fermentation of the culture medium in the scheme.
The invention has the beneficial effects that:
(1) the nutrient components and the effective components in the fermentation culture solution are better biodegraded, converted and recombined through fermentation, and the immunity activity of the final product is favorably improved.
(2) The prepared cordyceps sinensis fermentation product can well improve the immunity activity.
Detailed Description
The present invention is described in detail below with reference to specific examples, but the use and purpose of these exemplary embodiments are merely to exemplify the present invention, and do not set forth any limitation on the actual scope of the present invention in any form, and the scope of the present invention is not limited thereto.
Example 1
The culture medium for preparing the fermentation product for improving the immunity is prepared from the following raw materials in parts by weight:
3 parts of fine powder of the long-rooted mushroom,
3 parts of sparassis crispa fine powder,
4 parts of dendrobium officinale fine powder,
2 parts of a grifola frondosa extract,
3 parts of an agaricus blazei murill extract,
4 parts of a tuckahoe extract, namely tuckahoe extract,
1 part of a sulfur-containing bacterium extract,
4 parts of morinda officinalis and rhodiola rosea extracts,
3 parts of a phellinus pini karst extract,
3 parts of galacto-oligosaccharide,
80 parts of water.
The fermentation culture method of the culture medium comprises the following steps:
s1, inoculating the activated cordyceps militaris strain into a seed liquid culture medium to perform hericium erinaceus fermentation culture for 3-7 days to obtain cordyceps militaris liquid seed liquid; the seed liquid culture medium comprises the following components in parts by weight: 20 parts of potato, 2 parts of glucose, 0.05 part of magnesium sulfate and 0.02 part of monopotassium phosphate. The Cordyceps militaris strain is selected from Cordyceps No. 1.
S2, inoculating cordyceps militaris liquid seed liquid accounting for 2-5% of the volume of the culture medium into the culture medium, culturing for 5-8 days at 24-27 ℃, ending fermentation, and carrying out vacuum freeze drying on fermentation liquor to obtain a fermentation product.
Example 2
Referring to example 1, unlike example 1, a medium for preparing an immune-enhancing fermentation product according to the present example is prepared from the following raw materials in parts by weight:
4 parts of fine powder of the long-rooted mushroom,
5 parts of sparassis crispa fine powder,
5 parts of dendrobium officinale fine powder,
3 parts of a grifola frondosa extract,
5 parts of an agaricus blazei murill extract,
5 parts of a tuckahoe extract, namely tuckahoe extract,
2 parts of a sulfur-containing mushroom extract,
6 parts of morinda officinalis and rhodiola rosea extracts,
4 parts of a phellinus pini karst extract,
3 parts of galacto-oligosaccharide,
and 90 parts of water.
The method for fermentation culture of this medium is as described in example 1.
Example 3
Referring to example 1, unlike example 1, a medium for preparing an immune-enhancing fermentation product according to the present example is prepared from the following raw materials in parts by weight:
5 parts of fine powder of the long-rooted mushroom,
4 parts of sparassis crispa fine powder,
6 parts of dendrobium officinale fine powder,
4 parts of a grifola frondosa extract,
4 parts of an agaricus blazei murill extract,
6 parts of a tuckahoe extract, namely 6 parts of tuckahoe extract,
3 parts of a sulfur-containing bacterium extract,
5 parts of morinda officinalis and rhodiola rosea extracts,
3 parts of a phellinus pini karst extract,
3 parts of galacto-oligosaccharide,
100 parts of water.
The method for fermentation culture of this medium is as described in example 1.
Example 4
Animal experiments
1.1 male ICR mice with weight of 18-22g are randomly divided into a normal control group, a model control group, a positive control group (ginseng water extract is 2.0g/kg) and three dose groups (100, 200 and 300mg/kg) of fermentation product of example 2 after being adaptively fed for 3 days, 10 mice in each group are respectively gavaged to administer corresponding drugs 1 time per day for 15 consecutive days, the administration volume is 20mL/kg, the control group is administered with distilled water with equal volume, cyclophosphamide is subcutaneously injected for 50mg/kg, 0.1mL/10g and 1 time per day for 4 consecutive days on the 11 th day except the normal control group, 1:4 diluted ink is injected into tail vein after 1h of the last administration, 0.1mL/10g is injected, 20 muL of blood is respectively taken from the left and right retroorbital plexus of the mice after 2min and 10min after the injection, the mixed solution is placed in a test tube which is previously filled with 2mL of 0.1% Na2CO3, measuring absorbance (OD) at 600nm in a 96-well plate in 0.1 mL; at the same time, the thymus, spleen and liver of the mice were weighed, and the spleen weight (mg) and the thymus weight (mg) per g of the mice were used as the spleen index and the thymus index, and the K value and the phagocytosis index were calculated according to the following formulas.
Thymus coefficient ═ weight of thymus (mg)/weight (g); spleen coefficient spleen weight (mg)/body weight (g); k ═ K (logOD 1-logOD 2)/(t 2-t 1); α ═ K1/3 × body weight/(liver weight + spleen weight).
The results are shown in table 1:
TABLE 1 Effect of fermentations on mouse carbon clearance test (x. + -.s, n 10)
Note: p <0.05 comparison with model groups
As shown in table 1, mice lost weight after cyclophosphamide injection compared to the normal group, with statistical differences in the model group (P < 0.05). The phagocytic coefficient was increased for each administration group and positive group compared to the model group, with statistical differences between the fermentate 200 and 300mg/kg groups (P < 0.05). The results show that the fermentation product can promote the proliferation of thymus and spleen cells and enhance the phagocytic function of macrophages.
Therefore, the fermentation product has certain protection effect on cyclophosphamide induced mice immune reduction under 200 and 300mg/kg doses, and can enhance the phagocytic function of macrophages.
1.2 Effect on humoral immune function
60 ICR mice, male, with the weight of 18-22g, are randomly divided into a normal control group, a model control group, a positive control group (ginseng water extract 500m g/kg), and three fermentation product dose groups (100, 200 and 300mg/kg) of example 2, wherein 10 mice in each group are respectively subjected to intragastric administration of corresponding drugs, 1 time per day for 15 consecutive days, the administration volumes are 20mL/kg of body weight, and the control group is subjected to constant volume of normal saline; on day 11 of administration, except for normal control group, cyclophosphamide was subcutaneously injected at 50mg/kg 1 time per day for 4 consecutive days, on day 9, each group of mice was intraperitoneally injected with 0.2mL of 2% sheep red blood cells, 24 hours after the last administration, the body weight was weighed, blood was taken from the eyeball, serum was separated, and the following hemagglutination and half-maximal hemolysis value (HC) were performed50) And (4) measuring by the method.
(1) And (3) hemagglutination: diluting the serum with physiological saline, placing into micro hemagglutination experimental plate with 100ul per well, adding 100ul 0.5% (v/v) sheep red blood cell suspension, mixing, placing into a wet flat disc, covering, incubating at 37 deg.C for 3h, observing hemagglutination degree (grading 5), and calculating antibody volume.
The 0-level red blood cells all sink and are concentrated at the bottom of the hole to form a compact round point shape, and the liquid around the hole is clear.
Most of the I-grade red blood cells are deposited at the bottom of the hole to form a round point shape, and a small amount of agglutinated red blood cells are arranged at the periphery of the hole.
The level II agglutinated red blood cells form a thin layer at the bottom of the hole, and a loose red spot can be obviously seen at the center.
The level III agglutinated red blood cells are uniformly spread at the bottom of the hole to form a thin layer, and a small red spot is invisible at the center.
The grade IV agglutinated erythrocytes are uniformly spread at the bottom of the hole to form a thin layer, and the clumps are sometimes rolled up.
The antibody product is ═ epsilon (S1+2S2+3S3+4S4+ … … nSn). In the formula, 1, 2 and 3 … … n represent the index of the dilution ratio, S represents the grade of the agglutination degree, and the larger the antibody volume number, the higher the serum antibody.
(2) HC50 assay: diluting serum with SA buffer solution (generally 200 times and 500 times), placing 1mL of diluted serum into a test tube, sequentially adding 0.5mL of 10% (v/v) sheep red blood cell suspension, 1mL of complement (diluted with SA buffer solution 1: 8), additionally arranging a serum-free control tube (replaced by SA buffer solution), performing thermostatic water bath at 37 ℃ for 30min, stopping reaction by ice bath, centrifuging at 2000rpm for 10min, taking 1mL of supernatant, adding 3mL of Dushi reagent, simultaneously taking 0.25mL of 10% (v/v) sheep red blood cell suspension, adding 4mL of Dushi reagent, fully mixing, placing for 10min, and respectively measuring the optical density value of each tube with the control tube as a blank at 540 nm. Calculating HC50。
The results are shown in table 2:
TABLE 2 comparison of the number of mouse lectin antibody accumulations with HC50 values (x. + -. s, n 10)
Note: p <0.05, p <0.01 compared to model groups
As shown in Table 2, the number of antibody-producing cells and the serum hemolysin level of each group of mice were significantly decreased (P <0.01) compared to the normal group, and the number of antibody-producing cells and the serum hemolysin level of the fermentation products of 200 mg/kg and 300mg/kg were increased, with statistical differences (P <0.05) compared to the model group.
Therefore, the fermentation product has the effect of enhancing the body fluid immune function of a cyclophosphamide-induced mouse immune hypofunction model at the doses of 200 and 300 mg/kg.
The above-listed detailed description is only a specific description of a possible embodiment of the present invention, and they are not intended to limit the scope of the present invention, and equivalent embodiments or modifications made without departing from the technical spirit of the present invention should be included in the scope of the present invention.
Claims (7)
1. A culture medium for preparing a fermentation product for improving immunity is characterized by comprising the following components in parts by weight: 3-5 parts of fine powder of long-rooted mushroom, 3-5 parts of fine powder of sparassis crispa, 4-6 parts of fine powder of dendrobium officinale, 2-4 parts of grifola frondosa extract, 3-5 parts of agaricus blazei murill extract, 4-6 parts of morinda officinalis and rhodiola rosea extract, 4-6 parts of poria cocos extract, 1-3 parts of laetiporus sulphureus extract, 3-5 parts of phellinus pini extract, 3-5 parts of galacto-oligosaccharide and 80-100 parts of water.
2. The culture medium for preparing fermentation products for improving immunity according to claim 1, wherein the grifola frondosa extract, the agaricus blazei murill extract, the laetiporus sulphureus extract and the fomes pinicola extract are all edible fungus extracts; the edible fungus extracts are prepared by the following method: pulverizing corresponding edible and medicinal fungi, adding 20-30 times of water, extracting in shaking table at 40-50 deg.C for 12 hr, centrifuging to obtain supernatant, concentrating the supernatant under reduced pressure, and vacuum freeze drying to obtain corresponding edible and medicinal fungi extract.
3. The culture medium for preparing fermentation products for improving immunity according to claim 1, wherein the extract of Morinda citrifolia and rhodiola rosea is prepared by the following method: respectively crushing morinda officinalis and rhodiola rosea, and mixing the raw materials in a weight ratio of 1: mixing at a ratio of 1, adding 20-30 times of 50% vol% ethanol solution, extracting in shaking table at 40 deg.C for 12 hr, filtering to obtain supernatant, concentrating the supernatant under reduced pressure, and vacuum freeze drying to obtain radix Morindae officinalis and radix Rhodiolae extract.
4. A fermentation culture method of a culture medium is characterized by comprising the following steps:
(1) inoculating the activated Cordyceps militaris strain into a seed liquid culture medium, and performing fermentation culture for 3-7 days to obtain Cordyceps militaris liquid seed liquid;
(2) the method comprises the steps of firstly inoculating the cordyceps militaris liquid seed solution accounting for 2-5% of the volume of the culture medium into the culture medium of any one of claims 1-3, culturing for 5-8 days at the temperature of 24-27 ℃, finishing fermentation, and carrying out vacuum freeze drying on the fermentation liquor to obtain a fermentation product with the activity of improving immunity.
5. The method for fermentation culture of a culture medium according to claim 4, wherein in the step (1), the seed liquid culture medium comprises the following components in parts by weight: 20 parts of potato, 2 parts of glucose, 0.05 part of magnesium sulfate and 0.02 part of monopotassium phosphate.
6. The fermentation culture method of the culture medium according to claim 4, wherein the Cordyceps militaris strain of step (1) is selected from Cordyceps No. 1.
7. A fermentation product for enhancing immunity, which comprises the fermentation product having an enhanced immunity obtained by fermentation by the fermentation culture method of the medium according to claim 5 or 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110046373.2A CN112826080B (en) | 2021-01-14 | 2021-01-14 | Culture medium, fermentation culture method thereof and fermentation product capable of improving immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110046373.2A CN112826080B (en) | 2021-01-14 | 2021-01-14 | Culture medium, fermentation culture method thereof and fermentation product capable of improving immunity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112826080A true CN112826080A (en) | 2021-05-25 |
| CN112826080B CN112826080B (en) | 2022-06-17 |
Family
ID=75928124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110046373.2A Active CN112826080B (en) | 2021-01-14 | 2021-01-14 | Culture medium, fermentation culture method thereof and fermentation product capable of improving immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112826080B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940611A (en) * | 2010-08-25 | 2011-01-12 | 南京南农高科兽药研究所有限公司 | Plant source animal use immunopotentiator developed by cordyceps militaris fermented traditional Chinese medicine astragalus |
| CN101940313A (en) * | 2010-03-25 | 2011-01-12 | 无锡市天赐康生物科技有限公司 | Health food capable of enhancing immunity of human body and preparation method thereof |
-
2021
- 2021-01-14 CN CN202110046373.2A patent/CN112826080B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940313A (en) * | 2010-03-25 | 2011-01-12 | 无锡市天赐康生物科技有限公司 | Health food capable of enhancing immunity of human body and preparation method thereof |
| CN101940611A (en) * | 2010-08-25 | 2011-01-12 | 南京南农高科兽药研究所有限公司 | Plant source animal use immunopotentiator developed by cordyceps militaris fermented traditional Chinese medicine astragalus |
Non-Patent Citations (1)
| Title |
|---|
| 艾素、汤伟等: ""微生物发酵中草药及其活性物质的研究进展"", 《中国中药杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112826080B (en) | 2022-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101228951B (en) | Preparing method of biologic compound amylose nutrient fluid | |
| Boh et al. | Ganoderma lucidum and its pharmaceutically active compounds | |
| Mizuno | Development of an antitumor biological response modifier from Phellinus linteus (Berk. et Curt.) Teng (Aphyllophoromycetideae) | |
| Yang et al. | Production of exo-polymers by submerged mycelial culture of Cordyceps militaris and its hypolipidemic effect | |
| CN109528814B (en) | Microecological preparation of lactobacillus fermented astragalus membranaceus as well as preparation method and application of microecological preparation | |
| CN109452634B (en) | Fungus symbiotic fermentation blood sugar-reducing moringa oleifera and preparation method thereof | |
| KR101127271B1 (en) | Method of cultivating cordyceps sinensis and use of culture thereof | |
| CN104718987A (en) | Cordyceps sinensis chenopodium quinoa | |
| CN112826080B (en) | Culture medium, fermentation culture method thereof and fermentation product capable of improving immunity | |
| US20040106187A1 (en) | Composition for the culturing of Phellinus linteus mycelium | |
| CN104718986A (en) | Cordyceps sinensis Chinese yam | |
| CN112219956A (en) | Preparation and application of rosa roxburghii tratt edible fungus compound fermentation beverage for reducing blood fat and blood sugar | |
| KR100572405B1 (en) | Process for preparing nontoxic Rhus Verniciflua extract, and the use of the extract | |
| CN109439719A (en) | A kind of fungi two-way solid-fermented technique and its application based on Cortex Eucommiae | |
| CN107536061B (en) | Composite probiotic dietary fiber and preparation method thereof | |
| KR102580526B1 (en) | Method of Preparing Soybean Fermented Mycelium | |
| CN102643730B (en) | Tonic wine made of cordyceps militaris medium residue and preparation method thereof | |
| CN106074799A (en) | A kind of production method of Xinhui citrus reticulata edible fungi ferment | |
| Wei et al. | Anti-fatigue activity of extract form the submerged fermentation of Ganoderma Lucidum using Radix astragali as substrate | |
| CN112219923A (en) | Preparation and application of rosa roxburghii tratt edible fungus tea fermented beverage capable of reducing blood fat and blood sugar | |
| CN112913585A (en) | Preparation method of cordyceps sobolifera mycelium nutriment | |
| CN110876475A (en) | Medicinal and edible combined fermentation product and preparation method thereof | |
| CN104718989A (en) | Cordyceps sinensis dasheen | |
| CN104719782A (en) | Cordyceps sinensis mung beans | |
| CN104823690A (en) | Cordyceps sinensis and cordyceps millitaris buckwheat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |